MEDICREA Reports First Half 2020 Sales
09 Julio 2020 - 2:12AM
Business Wire
- COMMERCIAL ACTIVITY IMPACTED BY THE SPREAD OF THE COVID-19
PANDEMIC
- STRONG REVENUE RECOVERY IN JUNE : +3% WORLDWIDE AND +13
% IN THE US VS 2019
- 5,850 UNiD™ PERSONALIZED SURGERIES PERFORMED ON A CUMULATIVE
BASIS AS OF JUNE 30, 2020
The MEDICREA® Group (Euronext Growth Paris: FR0004178572 – ALMED
; OTCQX Best Market –MRNTF), pioneering the transformation of
spinal surgery through Artificial Intelligence, predictive modeling
and patient specific implants with its UNiD™ ASI (Adaptive Spine
Intelligence) proprietary software platform, services and
technologies, publishes sales for the first half of 2020.
(€ millions)
H1 2019
H1 2020
Variation
Variation at Constant Exchange
Rate
USA
Rest of the world
Total Sales
8.7
7.4
16.1
7.6
5.6
13.2
-13%
-24%
-18%
-15%
-24%
-19%
Sales for the 2nd quarter amounted to €5.8 million, bringing the
half-year total to €13.2 million, down 18% compared to the first
half of 2019 due to the COVID-19 pandemic. The postponement of many
elective surgeries since mid-March had a strong negative impact on
activity over this period.
As soon as the containment measures and the mobilization of
healthcare institutions in many countries were announced, MEDICREA®
prepared for the worst-case scenario, which was planned to have no
billings for the second quarter. Despite a very sharp drop in sales
in April and May, representing the equivalent of (-25%) and (-66%)
of a normative activity, respectively, June sales recovered
strongly, totaling €3.2 million, up +3% compared to the same period
last year, i.e. a sequential growth of +75% between May 2020 and
June 2020.
In June, the Group's three main markets performed well given the
health context:
- In the United States, sales were up by +13% compared to June
2019, despite the continued strong spread of COVID-19 in many
States; - In Belgium, growth was +12% over the same period; - Sales
in France are gradually returning to normal, with some regions
having regained good momentum while those most affected by the
pandemic are still under limited activity.
The use of UNiD™ patient-specific rods planning and
manufacturing services also shows a strong recovery with 144 UNiD®
personalized surgeries having taken place in the United States in
June, an increase of +33% compared to the same month of the
previous year, and 5,850 surgeries performed cumulatively as of
June 30, 2020 since the launch of this technology.
« We had planned for a difficult second quarter, but strategic
management of the crisis along with the favorable evolution of the
COVID-19 pandemic enabled us to resume business faster than
expected while generating very strong activity across our various
markets. Therefore, our sales recorded a clear rebound as of May
15. The strong sales generated in June 2020 for MEDICREA®
demonstrated a positive sign to the potential end of this crisis.
The current evolution of the health situation in the United States
and in the southern hemisphere obliges us, to remain cautious as
the catch-up effect that will inevitably occur is still anticipated
for the second half of 2020 but could be delayed by a few months. »
commented Denys Sournac, Founder, President and CEO of
MEDICREA®.
On June 30, 2020, the cash position was €13.2 million.
The strategic discussions which had resumed in May after a
period of interruption due to the spread of the COVID-19 epidemic,
are continuing to be very active.
Next publication: 2020 Half-Year results: September 14,
2020 after market
About MEDICREA® (www.medicrea.com)
Through the lens of predictive medicine, MEDICREA® leverages its
proprietary software analysis tools with big data and machine
learning technologies supported by an expansive collection of
clinical and scientific data. The Company is well-placed to
streamline the efficiency of spinal care, reduce procedural
complications and limit time spent in the operating room.
Operating in a $10 billion marketplace, MEDICREA® is a Small and
Medium sized Enterprise (SME) with 175 employees worldwide, which
includes 35 who are based in the U.S. The Company has an
ultra-modern manufacturing facility in Lyon, France housing the
development and production of 3D-printed titanium patient-specific
implants.
For further information, please visit: medicrea.com.
Connect with MEDICREA® FACEBOOK |
INSTAGRAM | TWITTER | WEBSITE | YOUTUBE
MEDICREA® is listed on EURONEXT Growth Paris
EnterNext PEA PME 150 Index ISIN: FR 0004178572 Ticker: ALMED LEI:
969500BR1CPTYMTJBA37
MEDICREA® is traded on OTCQX Best Market
Ticker: MRNTF
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200709005330/en/
MEDICREA® Denys SOURNAC Founder, Chairman and CEO
dsournac@medicrea.com
Fabrice KILFIGER Chief Financial Officer fkilfiger@medicrea.com
Tel: +33 (0)4 72 01 87 87